An upcoming study will look at an experimental delirium prevention care system to see if it can be effective in either preventing or ameliorating delirium in older patients in a hospital setting, a report in Trials explains.
An article in Schizophrenia Bulletin makes a strong case for a scaling up of schizophrenia care that could yield breakthroughs in treatment for the condition and, ultimately, many other mental health disorders. Such a scaling up would involve breaking down significant barriers but could yield significant breakthroughs in treatment.
As technology improves telemedicine is becoming a more viable option to treat a wide variety of conditions. While the idea of telemedicine can be easily implemented into practice there are still concerns that need to be addressed for the field to progress. These issues can include liability and governance over doctors and where their patients are located.
A study in JAMA Dermatology provides evidence that the use of two tests to assess cutaneous sarcoidosis disease severity should be expanded. The research has applications for dermatologists, rheumatologists, and pulmonologists, all of whom have a role in treating sarcoidosis.
Lidocaine metabolite N-ethylglycine (EG) relieves hyperalgesia and allodynia in animal models for chronic pain, suggests a study in Pain. The finding is an indicator that use of Glycine transporter 1 substrates might constitute a new drug target for the modulation of glycinergic inhibition in pain signaling.
A study in Translational Psychiatry has identified three potential genes that could prove to be responsible for disturbances in mitochondrial function and DNA repair mechanisms in bipolar disorder. The genes in question – POLG, OGG1, and NDUFV2 – may open new targets for examination. The study authors themselves consider the results to be “somewhat promising.”
Canada-based researchers examined the effectiveness of opioids for the long-term management of chronic neuropathic pain and found less than encouraging results, according to a study in The Journal of Pain.
The US Food and Drug Administration today announced it will permit Quest Diagnostics' Focus Diagnostics division to market a genital swab test for herpes simplex virus type 2.
An observational study of 657 people at high risk of getting HIV infections found that Gilead's Truvada taken daily has prevented them from getting the virus. The CDC is promoting the drug regimen in a campaign called PrEP, for pre-exposure prophylaxis.